The biology of VEGF and its receptors
The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Abstract
Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated in pathological angiogenesis associated with tumors, intraocular neovascular disorders and other conditions. The biological effects of VEGF are mediated by two receptor tyrosine kinases (RTKs), VEGFR-1 and VEGFR-2, which differ considerably in signaling properties. Non-signaling co-receptors also modulate VEGF RTK signaling. Currently, several VEGF inhibitors are undergoing clinical testing in several malignancies. VEGF inhibition is also being tested as a strategy for the prevention of angiogenesis, vascular leakage and visual loss in age-related macular degeneration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is well established that the formation of blood vessels occurs by angiogenesis and that vascular endothelial growth factor (VEGF) is a key molecule in promoting angiogenesis (Ferrara et al., 2003).”
From Molecular pathology of age-related macular degeneration (2009) · cites this paper as Ferrara et al., 2003
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Vascular Endothelial Growth Factor Is a Secreted Angiogenic Mitogen
Leung, D. W., Cachianes, G., Kuang, W.-J., Goeddel, D. V., & Ferrara, N. (1989) · Science · doi:10.1126/science.2479986 · Cited by 4,986 · cited 1×
“VEGF induces a potent angiogenic response in a variety of in vivo model”
BackgroundSelf-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Self-citationMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Tumor Cells Secrete a Vascular Permeability Factor That Promotes Accumulation of Ascites Fluid
Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983) · Science · doi:10.1126/science.6823562 · Cited by 3,972 · cited 1×
“VEGF is known also as vascular permeability factor, based on its ability to induce vascular leakag”
BackgroundFailure of blood-island formation and vasculogenesis in Flk-1-deficient mice
Shalaby, F., Rossant, J., Yamaguchi, T. P., Gertsenstein, M., Wu, X.-F., Breitman, M. L., & Schuh, A. C. (1995) · Nature · doi:10.1038/376062a0 · Cited by 3,931
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Self-citationVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Many molecules have been implicated as positive regulators of angiogenesis, including acidic fibroblast growth factor (FGF), basic FGF, transforming growth factor (TGF)-α, TGF-β, hepatocyte growth factor (HGF, or scatter factor), tumor necrosis factor-α, angiogenin, interleukin (IL)-8 and the angiopoietin”
Background
Research works printed but not linked: 3
- Presta, L.G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57, 4593–4599 (1997).
- Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res. 59, 5209–5218 (1999).
- Yang, J.C. et al. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Engl. J. Med. (in the press).
Cited by
Items 301–400 of 1,056
Biomarkers of endothelial activation/dysfunction in infectious diseases
Page, A. V., & Liles, W. C. (2013) · Virulence · doi:10.4161/viru.24530 · Cited by 270
Differentiation and Definition of Vascular-Targeted Therapies
Siemann, D. W., Bibby, M. C., Dark, G. G., Dicker, A. P., Eskens, F. A. L. M., Horsman, M. R., Marmé, D., & LoRusso, P. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.416.11.2 · Cited by 272
Morabito, A., De Maio, E., Di Maio, M., Normanno, N., & Perrone, F. (2006) · The Oncologist · doi:10.1634/theoncologist.11-7-753 · Cited by 274
Je, Y., Schutz, F. A., & Choueiri, T. K. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70222-0 · Cited by 280
Transcriptional Regulation of VEGF-A by the Unfolded Protein Response Pathway
Ghosh, R., Lipson, K. L., Sargent, K. E., Mercurio, A. M., Hunt, J. S., Ron, D., & Urano, F. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009575 · Cited by 270
“VEGFA is the major vascular endothelial growth factor and plays prominent roles in angiogenesis [32].”
BackgroundTargeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration
Ng, E. W. M., & Adamis, A. P. (2005) · Canadian Journal of Ophthalmology · doi:10.1016/s0008-4182(05)80078-x · Cited by 273
Lee, T.-H., Seng, S., Sekine, M., Hinton, C., Fu, Y., Avraham, H. K., & Avraham, S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040186 · Cited by 265
“VEGF binds to its cognate receptors VEGFR1 (also known as FLT1), VEGFR2 (also known as KDR or FLK1), and neuropilin 1 (NRP1) [8].”
BackgroundInfluentialAngiogenesis, Vasculogenesis, and Induction of Healing in Chronic Wounds
Bauer, S. M., Bauer, R. J., & Velazquez, O. C. (2005) · Vascular and Endovascular Surgery · doi:10.1177/153857440503900401 · Cited by 273
New Paradigms in Anticancer Therapy: Targeting Multiple Signaling Pathways With Kinase Inhibitors
FAIVRE, S., DJELLOUL, S., & RAYMOND, E. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.005 · Cited by 264
The role of neuropilins in cancer
Ellis, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0538 · Cited by 263
Human Studies of Angiogenic Gene Therapy
Gupta, R., Tongers, J., & Losordo, D. W. (2009) · Circulation Research · doi:10.1161/circresaha.109.200386 · Cited by 276
Molecular mechanism of VEGF and its role in pathological angiogenesis
Ahmad, A., & Nawaz, M. I. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30344 · Cited by 260
“Additionally, VEGF‐R2 is widely expressed in circulating endothelial progenitor cells, pancreatic duct cells, retinal progenitor cells, and megakaryocytes.(20) It is also involved with integrin‐dependent migration of ECs, and, upon binding of VEGF‐A, it undergoes conformational alteration to form a complex with integr…”
BackgroundZachary, I. (2005) · Neurosignals · doi:10.1159/000088637 · Cited by 266
“vascular endothelial growth factor (VEGF-A, VEGF or vascular permeability factor) has been established to be an essential regulator of angiogenesis in both vertebrate development and in a variety of common chronic human diseases [”
BackgroundAngiogenic factors in bone local environment
Chim, S. M., Tickner, J., Chow, S. T., Kuek, V., Guo, B., Zhang, G., Rosen, V., Erber, W., & Xu, J. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.03.008 · Cited by 264
“activities [72–74].”
Glomerular Structure and Function Require Paracrine, Not Autocrine, VEGF–VEGFR-2 Signaling
Sison, K., Eremina, V., Baelde, H., Min, W., Hirashima, M., Fantus, I. G., & Quaggin, S. E. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010030295 · Cited by 268
Zuniga, R. M., Torcuator, R., Jain, R., Anderson, J., Doyle, T., Ellika, S., Schultz, L., & Mikkelsen, T. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9718-y · Cited by 272
“The degree of VEGF overexpression and subsequent angiogenesis is directly proportional to tumor grade and overall outcome [5–7].”
BackgroundRemodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy
Ito, H., Koefoed, M., Tiyapatanaputi, P., Gromov, K., Goater, J. J., Carmouche, J., Zhang, X., Rubery, P. T., Rabinowitz, J., Samulski, R. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1190 · Cited by 274
“Specifically, VEGF is expressed by the perichondrium and hypertrophic chondrocytes and recruits endothelial cells to promote blood flow to the avascular tissu”
BackgroundPerivascular microglia promote blood vessel disintegration in the ischemic penumbra
Jolivel, V., Bicker, F., Binamé, F., Ploen, R., Keller, S., Gollan, R., Jurek, B., Birkenstock, J., Poisa-Beiro, L., Bruttger, J., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1372-1 · Cited by 265
Helm, C.-L. E., Fleury, M. E., Zisch, A. H., Boschetti, F., & Swartz, M. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503681102 · Cited by 269
Nanotechnology for angiogenesis: opportunities and challenges
Kargozar, S., Baino, F., Hamzehlou, S., Hamblin, M. R., & Mozafari, M. (2020) · Chemical Society Reviews · doi:10.1039/c8cs01021h · Cited by 262
Role of Notch and its oncogenic signaling crosstalk in breast cancer
Guo, S., Liu, M., & Gonzalez-Perez, R. R. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.12.002 · Cited by 260
“The expression of the VEGF gene is enhanced in a variety of angiogenic tumors including breast cancer [138,139].”
BackgroundKidoya, H., Ueno, M., Yamada, Y., Mochizuki, N., Nakata, M., Yano, T., Fujii, R., & Takakura, N. (2008) · The EMBO Journal · doi:10.1038/sj.emboj.7601982 · Cited by 265
“Among many molecules, vascular endothelial growth factors (VEGFs) and their cognate receptors (VEGFRs) play central roles in the differentiation (arterial), proliferation, migration and survival of ECs in physiological and pathological conditions (Ferrara et al, 2003).”
BackgroundPericytes regulate VEGF-induced endothelial sprouting through VEGFR1
Eilken, H. M., Diéguez-Hurtado, R., Schmidt, I., Nakayama, M., Jeong, H.-W., Arf, H., Adams, S., Ferrara, N., & Adams, R. H. (2017) · Nature Communications · doi:10.1038/s41467-017-01738-3 · Cited by 270
Self-citationGenetic Markers in Triple-Negative Breast Cancer
Sporikova, Z., Koudelakova, V., Trojanec, R., & Hajduch, M. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.07.023 · Cited by 262
Espinoza, J., Romero, R., Nien, J. K., Gomez, R., Kusanovic, J. P., Gonçalves, L. F., Medina, L., Edwin, S., Hassan, S., Carstens, M., et al. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.11.002 · Cited by 266
“Maternal age (y)† 27 (14-46) 23 (14-43) 24 (16-42) <.”
Alternative splicing: an emerging topic in molecular and clinical oncology
Pajares, M. J., Ezponda, T., Catena, R., Calvo, A., Pio, R., & Montuenga, L. M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70104-3 · Cited by 267
Endocrine and paracrine control of follicular development and ovulation rate in farm species
Hunter, M. G., Robinson, R. S., Mann, G. E., & Webb, R. (2004) · Animal Reproduction Science · doi:10.1016/j.anireprosci.2004.05.013 · Cited by 263
“VEGF mediates its action through two high affinity tyrosine kinase receptors named VEGF receptor (VEGFR)-1 and -2 (Ferrara et al., 2003).”
BackgroundVascular disrupting agents in clinical development
Hinnen, P., & Eskens, F. A. L. M. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603694 · Cited by 263
“It is a complex process in which vascular endothelial growth factor (VEGF) produced by tumour cells plays a predominant role (”
BackgroundChakraborty, G., Jain, S., & Kundu, G. C. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2126 · Cited by 266
“Previous results indicated that VEGF signaling represents a critical rate-limiting step in angiogenesis (7).”
BackgroundResultCovassin, L. D., Villefranc, J. A., Kacergis, M. C., Weinstein, B. M., & Lawson, N. D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506886103 · Cited by 264
Radke, D., Jia, W., Sharma, D., Fena, K., Wang, G., Goldman, J., & Zhao, F. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701461 · Cited by 256
Role of Receptor Tyrosine Kinase Transmembrane Domains in Cell Signaling and Human Pathologies
Li, E., & Hristova, K. (2006) · Biochemistry · doi:10.1021/bi060609y · Cited by 258
Takahashi, S. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.1785 · Cited by 261
VEGF may contribute to macrophage recruitment and M2 polarization in the decidua
Wheeler, K. C., Jena, M. K., Pradhan, B. S., Nayak, N., Das, S., Hsu, C.-D., Wheeler, D. S., Chen, K., & Nayak, N. R. (2018) · PLOS ONE · doi:10.1371/journal.pone.0191040 · Cited by 258
Heme Oxygenase-1 and the Vascular Bed: From Molecular Mechanisms to Therapeutic Opportunities
Loboda, A., Jazwa, A., Grochot-Przeczek, A., Rutkowski, A. J., Cisowski, J., Agarwal, A., Jozkowicz, A., & Dulak, J. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2043 · Cited by 265
“It is based on migration and proliferation of mature, differentiated endothelial cells, which are stimulated by various factors, including VEGF (126).”
Recent Advances in Scaffold Design and Material for Vascularized Tissue‐Engineered Bone Regeneration
Yin, S., Zhang, W., Zhang, Z., & Jiang, X. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801433 · Cited by 262
Mechanisms of lncRNA/microRNA interactions in angiogenesis
Zhao, Z., Sun, W., Guo, Z., Zhang, J., Yu, H., & Liu, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2019.116900 · Cited by 262
Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review)
Ahmad, R., Singh, J., Wunnava, A., Al‑Obeed, O., Abdulla, M., & Srivastava, S. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4847 · Cited by 189
Review: Hypoxia-Inducible Factor-1 (HIF-1): A Novel Transcription Factor in Immune Reactions
Hellwig-Bürgel, T., Stiehl, D. P., Wagner, A. E., Metzen, E., & Jelkmann, W. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.297 · Cited by 254
Tugues, S., Fernandez-Varo, G., Muñoz-Luque, J., Ros, J., Arroyo, V., Rodés, J., Friedman, S. L., Carmeliet, P., Jiménez, W., & Morales-Ruiz, M. (2007) · Hepatology · doi:10.1002/hep.21921 · Cited by 261
The Effect of Matrix Density on the Regulation of 3-D Capillary Morphogenesis
Ghajar, C. M., Chen, X., Harris, J. W., Suresh, V., Hughes, C. C. W., Jeon, N. L., Putnam, A. J., & George, S. C. (2008) · Biophysical Journal · doi:10.1529/biophysj.107.120774 · Cited by 264
Li, Z., Zhang, Y., Ying Ma, J., Kapoun, A. M., Shao, Q., Kerr, I., Lam, A., O’Young, G., Sannajust, F., Stathis, P., et al. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.092098 · Cited by 260
“Grades from 0 to 4 were given based on the severity of the glomerular lesions as follows: (1) grade 0: normal; (2) grade 1: mild capillary loop occlusion, no protein droplets; (3) grade 2: moderate capillary loop occlusion, 25% having protein droplets; (4) grade 3: severe capillary loop occlusion with 50% having prote…”
MethodBiomaterials tools to modulate the tumour microenvironment in immunotherapy
Chao, Y., & Liu, Z. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00004-6 · Cited by 245
Aptamer Nanomedicine for Cancer Therapeutics: Barriers and Potential for Translation
Lao, Y.-H., Phua, K. K. L., & Leong, K. W. (2015) · ACS Nano · doi:10.1021/nn507494p · Cited by 259
Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment
Madu, C. O., Wang, S., Madu, C. O., & Lu, Y. (2020) · Journal of Cancer · doi:10.7150/jca.44313 · Cited by 249
Molecular Control of Lymphatic Metastasis
Achen, M. G., & Stacker, S. A. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1413.020 · Cited by 260
RhoA/ROCK signaling is essential for multiple aspects of VEGF‐mediated angiogenesis
Bryan, B. A., Dennstedt, E., Mitchell, D. C., Walshe, T. E., Noma, K., Loureiro, R., Saint‐Geniez, M., Campaigniac, J., Liao, J. K., & Patricia, D. A. (2010) · The FASEB Journal · doi:10.1096/fj.09-145102 · Cited by 261
Cannabinoids Inhibit the Vascular Endothelial Growth Factor Pathway in Gliomas
Blázquez, C., González-Feria, L., Álvarez, L., Haro, A., Casanova, M. L., & Guzmán, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3927 · Cited by 255
“Thus, cannabinoid treatment lowered the expression of the following: (a) VEGF-A [confirming our previous Northern blot data (22)] and its relative VEGF-B (3, 4); (b) hypoxia-inducible factor-1 [one of the subunits of hypoxia-inducible factor-1, the major transcription factor involved in VEGF gene expression (29)]; (c)…”
BackgroundMethodChinnasamy, D., Yu, Z., Theoret, M. R., Zhao, Y., Shrimali, R. K., Morgan, R. A., Feldman, S. A., Restifo, N. P., & Rosenberg, S. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43490 · Cited by 253
Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 257
“Because of the key role of vascular endothelial growth factor (VEGF), anti-angiogenesis research in the past has been focused largely on this molecule.(3,4) This has resulted in Food and Drug Administration (FDA) approval of first-generation VEGF receptor inhibitors (VEGF(R)Is), such as the monoclonal anti-VEGF antibo…”
BackgroundMATHEMATICAL MODELING OF TUMOR-INDUCED ANGIOGENESIS
Chaplain, M. A. J., McDougall, S. R., & Anderson, A. R. A. (2006) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.8.061505.095807 · Cited by 255
Inducing Angiogenesis, a Key Step in Cancer Vascularization, and Treatment Approaches
Saman, H., Raza, S. S., Uddin, S., & Rasul, K. (2020) · Cancers · doi:10.3390/cancers12051172 · Cited by 232
“These growth factors have different levels of specificity and different affinities to tyrosine kinase receptors (VEGFR) 1,-2 and -3 [22].”
BackgroundArcondeguy, T., Lacazette, E., Millevoi, S., Prats, H., & Touriol, C. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt539 · Cited by 235
“VEGF-A affects both the development of new blood vessels (angiogenesis) and the survival of endothelial cells (vascular maintenance) by binding to the two tyrosine kinase receptors VEGFR1 and VEGFR2 (3,4).”
BackgroundINTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M. (2009) · Retina · doi:10.1097/iae.0b013e3181a94f01 · Cited by 255
Ohki, Y., Heissig, B., Sato, Y., Akiyama, H., Zhu, Z., Hicklin, D. J., Shimada, K., Ogawa, H., Daida, H., Hattori, K., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3496fje · Cited by 250
“VEGF-A mediates the angiogenic switch by interacting with two tyrosine kinase receptors, VEGFR1 (Flt-1) and VEGFR2 (Flk-1, KDR) (19, 20).”
BackgroundAngiogenesis in the Infarcted Myocardium
Cochain, C., Channon, K. M., & Silvestre, J.-S. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4849 · Cited by 244
“The angiogenic properties of VEGF during vascular development or tumor angiogenesis (29) have rapidly led to the evaluation of its role in post-MI angiogenesis.”
Rajakumar, A., Brandon, H. M., Daftary, A., Ness, R., & Conrad, K. P. (2004) · Placenta · doi:10.1016/j.placenta.2004.02.011 · Cited by 250
Molecular Physiology of Preconditioning-Induced Brain Tolerance to Ischemia
Obrenovitch, T. P. (2008) · Physiological Reviews · doi:10.1152/physrev.00039.2006 · Cited by 253
Burgess, T., Coxon, A., Meyer, S., Sun, J., Rex, K., Tsuruda, T., Chen, Q., Ho, S.-Y., Li, L., Kaufman, S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3329 · Cited by 252
Horsman, M. R., & Siemann, D. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2848 · Cited by 246
“induces significant vascular permeability and plays a key role in endothelial cell survival signaling in newly formed vessels (16, 17).”
BackgroundHDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells
Zeng, L., Xiao, Q., Margariti, A., Zhang, Z., Zampetaki, A., Patel, S., Capogrossi, M. C., Hu, Y., & Xu, Q. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200605113 · Cited by 251
“Flk-1 mediates not only VEGF-induced EC differentiation but also VEGF-induced mature endothelial function, such as proliferation, migration, permeability, and cell survival (Claesson-Welsh, 2003; Ferrara et al., 2003; Zachary, 2003; Coultas et al., 2005).”
Sbardella, D., Fasciglione, G. F., Gioia, M., Ciaccio, C., Tundo, G. R., Marini, S., & Coletta, M. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.10.015 · Cited by 247
“ADAM (a disintegrin and metalloprotease) proteases are type 1 transmembrane proteins, defined by a modular structure encompassing (i) a prodomain, whose removal in the trans-Golgi network by pro-protein convertases is a key step in protease activation (with the exception of ADAM8 and ADAM28, which are activated by an…”
BackgroundInfluentialVascular endothelial growth factor receptor-2 in breast cancer
Guo, S., Colbert, L. S., Fuller, M., Zhang, Y., & Gonzalez-Perez, R. R. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.04.004 · Cited by 246
“Therefore, the majority of VEGFR-2 actions are related to angiogenesis [18,19].”
BackgroundPGC-1 coactivators and skeletal muscle adaptations in health and disease
Arany, Z. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.07.018 · Cited by 246
“VEGF, the best studied of these factors, is a powerful activator of endothelial proliferation, permeability, and migration, and is critical for almost all forms of neovascularization [63].”
BackgroundBender, J. L. G., Adamson, P. C., Reid, J. M., Xu, L., Baruchel, S., Shaked, Y., Kerbel, R. S., Cooney-Qualter, E. M., Stempak, D., Chen, H. X., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9230 · Cited by 249
Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications
Herbst, R. S., Onn, A., & Sandler, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.18.853 · Cited by 246
A new perspective on lipid research in age-related macular degeneration
van Leeuwen, E. M., Emri, E., Merle, B. M. J., Colijn, J. M., Kersten, E., Cougnard-Gregoire, A., Dammeier, S., Meester-Smoor, M., Pool, F. M., de Jong, E. K., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.04.006 · Cited by 247
“VEGF is a key molecule in promoting angiogenesis and potentially inducing vascular leakage and inflammation by triggering the increased production and permeability of capillary endothelial cells (Ferrara et al., 2003).”
BackgroundRetinal and choroidal angiogenesis: pathophysiology and strategies for inhibition
Das, A., & McGuire, P. G. (2003) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2003.08.001 · Cited by 242
Stimulation of bone repair with ultrasound: A review of the possible mechanic effects
Padilla, F., Puts, R., Vico, L., & Raum, K. (2014) · Ultrasonics · doi:10.1016/j.ultras.2014.01.004 · Cited by 234
“It regulates mitogenesis and the recruitment of endothelial cells [102], and is involved in osteoblasts differentiation and osteoclasts activation [103,104] (Fig.”
BackgroundSpatio‐temporally precise activation of engineered receptor tyrosine kinases by light
Grusch, M., Schelch, K., Riedler, R., Reichhart, E., Differ, C., Berger, W., Inglés‐Prieto, Á., & Janovjak, H. (2014) · The EMBO Journal · doi:10.15252/embj.201387695 · Cited by 245
“In addition to their prominent role in cancer, growth factors are important inducers of angiogenesis in physiological and pathophysiological conditions (Ferrara et al, 2003; Presta et al, 2005).”
BackgroundLi, X., Chen, Y., Wang, M., Ma, Y., Xia, W., & Gu, H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.072 · Cited by 239
“It is well known that the vascular endothelial growth factor (VEGF) plays a critical role in thepathological angiogenesis in tumors [41,42].”
BackgroundLee, J.-H., Canny, M. D., De Erkenez, A., Krilleke, D., Ng, Y.-S., Shima, D. T., Pardi, A., & Jucker, F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509069102 · Cited by 242
Role of shear-stress-induced VEGF expression in endothelial cell survival
dela Paz, N. G., Walshe, T. E., Leach, L. L., Saint-Geniez, M., & D'Amore, P. A. (2012) · Journal of Cell Science · doi:10.1242/jcs.084301 · Cited by 236
“VEGF also promotes EC migration and survival as well as the formation and maintenance of capillary fenestrations (Ferrara et al., 2003; Maharaj and D’Amore, 2007).”
BackgroundVEGF-A in Cardiomyocytes and Heart Diseases
Braile, M., Marcella, S., Cristinziano, L., Galdiero, M. R., Modestino, L., Ferrara, A. L., Varricchi, G., Marone, G., & Loffredo, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155294 · Cited by 234
Sustained delivery of vascular endothelial growth factor with alginate beads
Gu, F., Amsden, B., & Neufeld, R. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.02.021 · Cited by 246
VEGF as a potential target in lung cancer
Frezzetti, D., Gallo, M., Maiello, M. R., D’Alessio, A., Esposito, C., Chicchinelli, N., Normanno, N., & De Luca, A. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1371137 · Cited by 235
“mic domain with tyrosine kinase activity [8].”
BackgroundPolyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis
Scarlato, M., Previtali, S. C., Carpo, M., Pareyson, D., Briani, C., Del Bo, R., Nobile-Orazio, E., Quattrini, A., & Comi, G. P. (2005) · Brain · doi:10.1093/brain/awh519 · Cited by 241
“The human VEGF gene gives rise to six different protein isoforms (Ferrara et al., 2003).”
Stimulation of proangiogenesis by calcium silicate bioactive ceramic
Li, H., & Chang, J. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.10.019 · Cited by 241
“Many results have indicated that NO is an important messenger of KDR in the cascade of regulating endothelial cell migration and angiogenesis, as activation of KDR can initiate many downstream cascades in regulating endothelial cell migration, including activation of eNOS and subsequently NO expression [59,63].”
BackgroundMasoumi Moghaddam, S., Amini, A., Morris, D. L., & Pourgholami, M. H. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9337-5 · Cited by 228
“itor cells, and megakaryocytes [30].”
Vascular endothelial growth factor and diabetic complications
WIROSTKO, B., WONG, T., & SIMO, R. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.09.002 · Cited by 241
Targeting VEGF-A to Treat Cancer and Age-Related Macular Degeneration
Ferrara, N., Mass, R. D., Campa, C., & Kim, R. (2007) · Annual Review of Medicine · doi:10.1146/annurev.med.58.061705.145635 · Cited by 238
Self-citationChapter 4 An Optimized Three‐Dimensional In Vitro Model for the Analysis of Angiogenesis
Nakatsu, M. N., & Hughes, C. C. W. (2008) · Methods in Enzymology · doi:10.1016/s0076-6879(08)02004-1 · Cited by 235
“VEGF in particular is a critical angiogenic factor and on binding of VEGF to its receptor VEGFR-2, EC responses such as proliferation, differentiation, and migration are elicited (Ferrara et al., 2003).”
BackgroundRole of eNOS in neovascularization: NO for endothelial progenitor cells
Duda, D. G., Fukumura, D., & Jain, R. K. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.02.001 · Cited by 240
Phage Nanofibers Induce Vascularized Osteogenesis in 3D Printed Bone Scaffolds
Wang, J., Yang, M., Zhu, Y., Wang, L., Tomsia, A. P., & Mao, C. (2014) · Advanced Materials · doi:10.1002/adma.201400154 · Cited by 239
Cabric, S., Sanchez, J., Lundgren, T., Foss, A., Felldin, M., Källen, R., Salmela, K., Tibell, A., Tufveson, G., Larsson, R., et al. (2007) · Diabetes · doi:10.2337/db07-0358 · Cited by 238
“Heparin has an affinity for a number of plasma proteins and growth factors (35), such as vascular endothelial growth factor (36) and fibroblast growth factor (37), which may facilitate revascularization and reinnervation.”
BackgroundMolecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes
Backer, M. V., Levashova, Z., Patel, V., Jehning, B. T., Claffey, K., Blankenberg, F. G., & Backer, J. M. (2007) · Nature Medicine · doi:10.1038/nm1522 · Cited by 243
“VEGF receptors, the main target for emerging anti-angiogenic therapie”
BackgroundClinical development of targeted and immune based anti-cancer therapies
Seebacher, N. A., Stacy, A. E., Porter, G. M., & Merlot, A. M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1094-2 · Cited by 231
A direct and melanopsin-dependent fetal light response regulates mouse eye development
Rao, S., Chun, C., Fan, J., Kofron, J. M., Yang, M. B., Hegde, R. S., Ferrara, N., Copenhagen, D. R., & Lang, R. A. (2013) · Nature · doi:10.1038/nature11823 · Cited by 240
Self-citationDemidova-Rice, T. N., Hamblin, M. R., & Herman, I. M. (2012) · Advances in Skin & Wound Care · doi:10.1097/01.asw.0000418541.31366.a3 · Cited by 236
“Fibroblast growth factor 7, which currently is FDA approved for treatment of oral mucositis,(15) was shown to enhance the repair of venous ulcers in a phase 2A clinical trial,(27) but failed to increase the percentage of wounds fully healed within the 20 weeks of the study.(28) This failure has been attributed to insu…”
BackgroundHuang, Y., Chen, X., Dikov, M. M., Novitskiy, S. V., Mosse, C. A., Yang, L., & Carbone, D. P. (2007) · Blood · doi:10.1182/blood-2007-01-065714 · Cited by 230
Ocular delivery of macromolecules
Kim, Y. C., Chiang, B., Wu, X., & Prausnitz, M. R. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.043 · Cited by 232
“Anti-VEGF therapies bind to the VEGF signaling peptide with high affinity to neutralize VEGF's downstream effect of promoting the growth of leaky immature vessels [9].”
BackgroundBevacizumab Safety in Patients with Central Nervous System Metastases
Besse, B., Lasserre, S. F., Compton, P., Huang, J., Augustus, S., & Rohr, U.-P. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2439 · Cited by 241
“Clin Cancer Res; 16(1) January 1, 2010 forme, two patients in the bevacizumab arm (2.”
BackgroundInfluentialPas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation
Shalapour, S., & Karin, M. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.021 · Cited by 228
“While being the major mediator of vascular permeability during the initiation phase, VEGF stimulates formation of new blood vessels during resolution and healing (Ferrara et al., 2003).”
BackgroundDrogat, B., Auguste, P., Nguyen, D. T., Bouchecareilh, M., Pineau, R., Nalbantoglu, J., Kaufman, R. J., Chevet, E., Bikfalvi, A., & Moenner, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3235 · Cited by 220
“See also Supplementary Fig. S5. Cancer Research Cancer Res 2007; 67: ( 14 ).”
BackgroundInfluentialYi, T., Yi, Z., Cho, S.-G., Luo, J., Pandey, M. K., Aggarwal, B. B., & Liu, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5944 · Cited by 237
“VEGFR2 is the primary receptor in VEGF signaling pathway that regulates endothelial cell proliferation, migration, differentiation, tube formation, and angiogenesis (14, 15).”
BackgroundJin, Q., Hemminki, K., Enquist, K., Lenner, P., Grzybowska, E., Klaes, R., Henriksson, R., Chen, B., Pamula, J., Pekala, W., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1803 · Cited by 239
“Angiogenesis is an important step in the development of cancer and is necessary for primary tumor growth, invasiveness, and metastasis (1).”
BackgroundAtienzar‐Aroca, S., Flores‐Bellver, M., Serrano‐Heras, G., Martinez‐Gil, N., Barcia, J. M., Aparicio, S., Perez‐Cremades, D., Garcia‐Verdugo, J. M., Diaz‐Llopis, M., Romero, F. J., et al. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12834 · Cited by 231
“Moreover, oxidative stress induces the formation of angiogenic factors, of which VEGF is most commonly known [19].”
BackgroundBiodegradable collagen patch with covalently immobilized VEGF for myocardial repair
Miyagi, Y., Chiu, L. L. Y., Cimini, M., Weisel, R. D., Radisic, M., & Li, R.-K. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.10.007 · Cited by 232
Gaudio, E., Barbaro, B., Alvaro, D., Glaser, S., Francis, H., Ueno, Y., Meininger, C. J., Franchitto, A., Onori, P., Marzioni, M., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.034 · Cited by 236
Brahimi-Horn, M. C., & Pouysségur, J. (2009) · Journal of Cell Science · doi:10.1242/jcs.035022 · Cited by 226
“This phenomenon is known as angiogenesis, which is an adaptive response that attempts to compensate for the low oxygen level in tissues (Ferrara et al., 2003).”
Background
Metadata
- Authors
- Ferrara, N., Gerber, H.-P., & LeCouter, J.
- Affiliations
- Genentech (US)
- Corresponding author
- Ferrara, Napoleone
- Venue
- Nature Medicine
- Published
- 2003-06-01
- Volume
- 9
- Issue
- 6
- Pages
- 669-676
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2000292756
- Cited by
- 9,591
- References
- 144
- Citations by year
- 2026: 154 · 2025: 270 · 2024: 292 · 2023: 317 · 2022: 336 · 2021: 386 · 2020: 379 · 2019: 403 · 2018: 384 · 2017: 466 · 2016: 460 · 2015: 485 · 2014: 551 · 2013: 527 · 2012: 580
- FWCI
- 28.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- vascular endothelial growth factor, VEGF receptors, VEGFR1, VEGFR2, receptor tyrosine kinase signaling, angiogenesis, pathological angiogenesis, tumor angiogenesis, intraocular neovascularization, VEGF inhibitors, age-related macular degeneration, vascular leakage, embryonic development
- MeSH terms
- Animals, Clinical Trials as Topic, Endothelium, Vascular, Growth Substances, Humans, Lymphokines, Neovascularization, Pathologic, Oxygen, Signal Transduction, Endothelial Growth Factors, Neovascularization, Physiologic, Protein Isoforms, Intercellular Signaling Peptides and Proteins, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.